Jane Street Group LLC increased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 362.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,997 shares of the company's stock after buying an additional 49,366 shares during the period. Jane Street Group LLC's holdings in HUTCHMED were worth $1,305,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the business. Rhumbline Advisers lifted its position in shares of HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after buying an additional 564 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of HUTCHMED by 74.8% during the 2nd quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock worth $2,248,000 after purchasing an additional 56,200 shares during the period. Vanguard Personalized Indexing Management LLC increased its position in HUTCHMED by 9.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company's stock worth $226,000 after buying an additional 1,168 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of HUTCHMED during the 2nd quarter worth $213,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of HUTCHMED during the second quarter worth $279,000. 8.82% of the stock is currently owned by institutional investors.
HUTCHMED Price Performance
Shares of NASDAQ HCM traded down $0.20 during midday trading on Friday, hitting $14.27. 34,629 shares of the company traded hands, compared to its average volume of 114,918. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The stock has a 50-day moving average price of $17.32 and a 200 day moving average price of $17.98.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Check Out Our Latest Research Report on HCM
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
